Cost-utility of azithromycin in patients with severe asthma.

Jefferson Antonio BuendiaDiana Guerrero PatiñoJohn Edwin Feliciano-Alfonso

Published in: The Journal of asthma : official journal of the Association for the Care of Asthma (2021)

Add-on therapy with azithromycin was found to be cost-effective when added to usual care in patients who remain uncontrolled despite treatment with medium or high-dose ICS/LABA.

Keyphrases

high dose
healthcare
palliative care
low dose
stem cell transplantation
pain management
bone marrow
cell therapy